Monica Lo Russo (@monica_lorusso) 's Twitter Profile
Monica Lo Russo

@monica_lorusso

Radiation Oncologist, Universität Klinikum Tübingen

ID: 713079459453210629

calendar_today24-03-2016 19:06:06

66 Tweet

26 Followers

46 Following

Pfizer Inc. (@pfizer) 's Twitter Profile Photo

UPDATE: We are proud to announce, along with BioNTech SE, that our mRNA-based #vaccine candidate has, at an interim analysis, demonstrated initial evidence of efficacy against #COVID19 in participants without prior evidence of SARS-CoV-2 infection.

Cihan Gani (@gi_radonc) 's Twitter Profile Photo

🚨Fully autonomous MRgRT planning at Uniklinikum Tübingen . 👉Prostate Cx 👉Segmentation by #AI TheraPanacea 👉Plan generation: Particle swarm by L. Künzel and @D_Thorwarth bit.ly/3qWMpvb 👉First #radonc involvement: Simon Boeke plan adaptation at 1.5T #MRLinac Elekta

🚨Fully autonomous MRgRT planning at <a href="/uktuebingen/">Uniklinikum Tübingen</a> .
👉Prostate Cx 
👉Segmentation by #AI <a href="/TheraPanacea/">TheraPanacea</a> 
👉Plan generation: Particle swarm by L. Künzel and @D_Thorwarth bit.ly/3qWMpvb
👉First #radonc involvement: <a href="/BoekeSimon/">Simon Boeke</a> plan adaptation at 1.5T #MRLinac <a href="/Elekta/">Elekta</a>
JAMA Oncology (@jamaonc) 's Twitter Profile Photo

Comprehensive cardiac substructure radiation dose analysis shows LAD coronary V15 Gy associated with major adverse cardiac events and mortality in locally advanced NSCLC, particularly in patients without baseline heart disease. Katelyn Atkins, MD, PHD Ray Mak, MD ja.ma/34iO1FK

Cihan Gani (@gi_radonc) 's Twitter Profile Photo

#Santa came to visit us at the #MRlinac Uniklinikum Tübingen today. But look what he did... Oh Santa 🎅... #Xmas #xmas2020 #radonc #mrl #medphys @elekta

Memorial Sloan Kettering Cancer Center (@mskcancercenter) 's Twitter Profile Photo

🚨 Breaking #ASCO22 News: Breakthrough findings published in NEJM by MSK experts Andrea Cercek & Luis Diaz show 100% complete response rate in all patients who received #immunotherapy treatment for mismatch repair deficient locally advanced #RectalCancer. bit.ly/3NnXSib

Gil Morgan, MD (@weoncologists) 's Twitter Profile Photo

The 4⃣th NEJM from #ASCO22 DESTINY Breast04 Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced #BreastCancer ✅trastuzumab deruxtecan resulted in significantly longer PFS &OS🆚Chemo🧪 ✅OS 23.9 mo🆚17.5 mo ✅PFS 10.1🆚5.4 mo OncoAlert 🚨 nejm.org/doi/full/10.10…

The 4⃣th <a href="/NEJM/">NEJM</a> from #ASCO22
DESTINY Breast04
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced #BreastCancer

✅trastuzumab deruxtecan resulted in significantly longer PFS &amp;OS🆚Chemo🧪

✅OS 23.9 mo🆚17.5 mo
✅PFS 10.1🆚5.4 mo

<a href="/OncoAlert/">OncoAlert</a> 🚨

nejm.org/doi/full/10.10…
ESTRO (@estro_rt) 's Twitter Profile Photo

Explore the latest in #radiobiology at #ESTRO25! From predictive molecular signatures to #flash #radiotherapy, #DNA damage response, and tumour microenvironment shaping, join us for expert-led sessions, stimulating debates, and #networking. 👉 bit.ly/411I8Lg

Explore the latest in #radiobiology at #ESTRO25! From predictive molecular signatures to #flash  #radiotherapy, #DNA damage response, and tumour microenvironment shaping, join us for expert-led sessions, stimulating debates, and #networking.
👉 bit.ly/411I8Lg
Matthias Guckenberger (@mat_guc) 's Twitter Profile Photo

Today is HCC day! - RTOG 1112 - HCC unsuitable for or refractory to local-regional Tx (n=177) - SBRT & Sorafenib vs Sorafenib - After adjustment for stratification factors, improved OS after SBRT (HR 0.72) - Median PFS improved from 5.5 to 9.2 mo (HR 0.55) jamanetwork.com/journals/jamao…